This transcript has been lightly edited for clarity; captions are auto-generated.

An article published in TechTarget referenced a study published in the January 2026 issue of The American Journal of Managed ...

Targeted therapies for MASH show progress, with pegozafermin leading in efficacy for fibrosis regression and disease resolution. New research highlights the effectiveness of targeted therapies for ...

Access to biologic therapy, such as omalizumab, is a significant barrier for CSU patients in Latin America, despite high disease knowledge. Participants in the pilot program had high baseline ...

The rapid proliferation of high-efficacy disease-modifying therapies for multiple sclerosis (MS) has revolutionized the treatment landscape, yet significant gaps remain in how health systems organize ...

Overall, the “Hidradenitis Suppuritiva Update 2026” session underscored a new treatment paradigm: HS care in 2026 requires early diagnosis, systemic screening, combination medical therapy, and ...

Favorable outcomes were found when artificial intelligence (AI) was used in mammography screenings compared with the standard double reading in a new study published in The Lancet. 1 The use of AI was ...

Economic Realities: Pharma leadership is often conditioned for the "high-risk, high-reward" physics of pipeline assets. MedTech operates on iterative innovation and service-heavy models. Bridging ...

Manjool Shah, MD, clinical associate professor of ophthalmology and visual sciences for the Kellogg Eye Center, discussed how ...

ASH 2025 immunotherapy data highlight the importance of treatment sequencing, real-world outcomes in high-risk populations, ...

Data at ASH 2025 highlighted that standardized workflows, education, monitoring innovations, and collaboration are steadily ...

Adopting zanubrutinib for the treatment of chronic lymphocytic leukemia showed improved tolerability and persistence, ...